Note: Personalized Cancer Vaccines: A New Frontier in Thailand's Fight Against Cancer

Personalized Cancer Vaccines: A New Frontier in Thailand's Fight Against Cancer

Date: 15 May 2026

Time: 12:00 PM, UTC+08:00

Format: Virtual

Access Information

A dedicated zoom link has been sent out to you. if you have not received it, please reach out to Secretariat@wicapac.com

Event Details:

Join us for an insightful session on “Personalized Cancer Vaccines: A New Frontier in Thailand’s Fight Against Cancer”, exploring the latest advancements in precision medicine and cancer immunotherapy.

The session will be led by Dr. Trairak Pisitkun, MD, a physician-scientist and leader in systems biology and cancer immunotherapy. With extensive experience at the U.S. National Institutes of Health (NIH) and in building Thailand’s capabilities in proteomics and computational biology, Dr. Pisitkun will share valuable insights into the development and future of personalized cancer vaccines.

What You Will Learn

Key concepts and recent advances in personalized cancer vaccines
The role of precision medicine in modern oncology
Thailand’s contributions to biologics and immunotherapy innovation
Challenges and opportunities in clinical translation

Speaker

Dr. Trairak Pisitkun, MD
Faculty of Medicine, Chulalongkorn University
Deputy Director, Queen Saovabha Memorial Institute (Thai Red Cross Society)
Chief Medical Officer & Co-founder, Seqker Biosciences

We look forward to your participation.

Best regards,

WIC APAC Secretariat

On behalf of World Immunotherapy Council Asian Chapter &

Thailand Hub of Talents in Cancer Immunotherapy

โชคดีที่เวลาว่างตรงกันพอดี ก็เลยได้มีโอกาสฟังงานใหม่ของ อ.ไตรลักษณ์ พิสิษฐ์กุล และการได้ฟังแบบ live ก็ทำให้เรามีโอกาสได้ถามคำถาม ถ้าเวลาเหลืออยู่ หนึ่งในนั้นคือเรื่อง neoantigen dynamics during disease progression การรักษามะเร็วดูแล้ว poteintial ที่จะรักษาให้หายขาดน่าจะยาก ถ้าอยู่ใน stage ท้าย ๆ แล้ว แต่งานทางด้าน immunotherapy น่าจะช่วยให้คุณภาพชีวิตของผู้ป่วยดีขึ้นอย่างแน่นอน และความสามารถของไทยในการที่จะทำการรักษาเหล่านี้ต้องมี infrastructure ที่ดี และการผลิต peptide และการทำนาย anticancer peptide ยังคงมีความท้าทายอยู่พอสมควร และคนเข้าถึงการรักษาแบบนี้ได้ ยังคงจำกัดอยู่ เนื่องจากเทคโนโลยียังไม่ถูก

Pipeline ที่ prioritize เพื่อให้ได้ top-10 หรือ top-20 ในการเตรียมเป็น therapetic vaccine ยังมีปัญหาเรื่อง aggregation เนื่องมาจาก peptide มันจับตัวกัน ทำให้ยากต่อการฉีดเข้าที่กล้ามเนื้อ ในอนาคตฐานข้อมูลเรื่อง solubility น่าจะดีขึ้นกว่าเดิม และสามารถเอาไป integrate เข้าไปใน pipeline ได้

ไม่สามารถดาวน์โหลด full-text ได้แต่มีใน MedRxiv: https://www.medrxiv.org/content/10.64898/2025.12.02.25341434v1

Note ระหว่างการฟัง และถาม gemini ไปด้วย เพื่อบันทึกไว้กันลืม

The provided image outlines a comprehensive Neoantigen Identification and Vaccination Platform, which is a personalized cancer immunotherapy workflow. The goal is to identify unique mutations in a patient's tumor and create a custom vaccine to trigger an immune response against those specific cancer cells.

Here is a breakdown of the workflow:

1. Data Acquisition (Sample Collection)

The process begins by taking four types of samples from the patient to compare healthy tissue against cancerous tissue:

Normal DNA: Usually from blood or healthy tissue.
Tumor DNA: From the biopsy of the tumor.
Tumor RNA: To see which genes are actually being expressed (turned on).
Tumor Proteins: To identify which peptides are physically present on the cell surface.

2. Sequencing and Multi-Omics Analysis

The platform uses different high-throughput technologies to process these samples:

WES (Whole Exome Sequencing): Compares Normal and Tumor DNA using tools like Mutect2, Strelka, and Varscan to perform Somatic Mutation Calling. This identifies mutations that exist only in the tumor.
RNA-seq: Uses tools like Kallisto to quantify gene expression levels. This ensures the identified mutation is actually being produced by the cell.
HLA Pulldown & MS-based Immunopeptidomics: Uses Mass Spectrometry (processed via MaxQuant or PEAKS) to find the "Peptidome"—the actual fragments of proteins currently presented by the cell's HLA (Human Leukocyte Antigen) system.

3. Neoantigen Prediction

Once mutations are identified, the system must predict which ones will most likely be recognized by the immune system:

HLA Typing: Tools like Athlates and Optitype determine the patient’s specific HLA type (the "docking station" for antigens).
Binding Prediction: Software like NetMHCpan4.0 predicts how strongly a mutated peptide will bind to the patient's HLA.
Pipeline Integration: Tools like MuPeXI and pVACseq integrate the sequencing data, expression levels, and binding affinity to rank the best "neoantigen" candidates.

4. Vaccine Production and Validation

The final stages move from digital prediction to clinical application:

GMP Laboratory: The top-ranked neoantigens are manufactured into an RNA or Peptide Vaccine under strict clinical standards (Good Manufacturing Practice).
Immunological Testing: Before or after administration, the vaccine's effectiveness is tested using assays like ELISpot or CFC (Cytokine Flow Cytometry) to see if the patient’s T-cells are actually attacking the predicted targets.

Key Summary of Software/Tools Mentioned:

Category	Tools Listed
Mutation Calling	Mutect2, Strelka, Varscan
HLA Typing	Athlates, Optitype
Expression/Quant	Kallisto
Proteomics	MaxQuant, PEAKS
Prioritization	MuPeXI, pVACseq, NetMHCpan4.0

This "bench-to-bedside" approach ensures that the vaccine is 100% tailored to the specific genetic profile of an individual's tumor.

In the context of the platform you shared, the question of whether HLA "preserves" can refer to two different things: its biological stability (how long the peptide-HLA complex stays on the cell surface) and its technical preservation (how well the HLA proteins/genes survive in lab samples).

1. Biological Preservation (Peptide-HLA Stability)

In immunology, "preservation" often refers to pHLA complex stability. For a neoantigen to be a good vaccine candidate, the HLA molecule must "preserve" or hold onto the peptide long enough for a T-cell to find it.

The Problem: Many peptides bind to HLA briefly and then fall off. If the complex isn't stable, the immune system won't see it.
The Workflow Role: The platform uses tools like NetMHCpan4.0 to predict this. Research shows that stability (how long it stays bound) is often a better predictor of vaccine success than affinity (how strongly it binds).

2. Technical Preservation (Sample Storage)

If you are asking if HLA survives in the tumor samples shown on the left of your diagram (Normal DNA, Tumor DNA, etc.):

DNA/RNA (WES & RNA-seq): The genetic sequence of your HLA is very stable. Even in archived samples (like FFPE blocks), we can usually "type" your HLA to see which alleles you have.
Proteins (HLA Pulldown): This is more delicate. HLA proteins are best preserved in Fresh-Frozen (FF) samples. While they can be detected in Formalin-Fixed (FFPE) samples, the fixation process can cross-link proteins, making the "Pulldown" step in your diagram much harder.
Loss of Heterozygosity (LOH): Sometimes the tumor "doesn't preserve" the HLA naturally. In a process called HLA escape, tumors can delete one of their HLA genes. If this happens, even if you identify a great neoantigen, the tumor won't present it, and the vaccine may fail.

3. "Does it preserve" in the platform workflow?

In the specific image you provided:

HLA typing is used to identify your "immune fingerprint."
HLA Pulldown is used to physically capture the HLA molecules to see what they are actually holding.
MS-based Immunopeptidomics then identifies the exact peptides being "preserved" or presented by those HLA molecules.

In short: HLA genetics are well-preserved in samples, but HLA protein expression on tumor cells is often unstable or intentionally "lost" by the cancer to hide from your immune system.

Does your research involve looking at how these HLA levels change after treatment, or are you focused more on the initial identification?

In molecular biology, the term "conserved" has two distinct meanings depending on whether you are looking at the sequence (evolution) or the individual (genetics).

1. Evolutionary Conservation: Low

In the broad context of biology, HLA (Human Leukocyte Antigen) is one of the least conserved regions in the human genome. * High Polymorphism: Evolution has favored extreme diversity in the HLA region. This "diversifying selection" ensures that as a species, humans can recognize a vast array of different pathogens.

Species Comparison: While the basic structure of the MHC (Major Histocompatibility Complex) is conserved across most vertebrates, the specific HLA genes in humans are significantly different from those in other species, and even between different human populations.

2. Structural & Functional Conservation: High

While the specific amino acids that bind to peptides vary wildly, the three-dimensional structure of the HLA molecule is highly conserved.

The "Peptide Groove": Whether you have HLA-A2 or HLA-B27, the physical architecture—the "cradle" that holds the peptide—remains fundamentally the same.
CD8/CD4 Binding Sites: The regions where T-cell co-receptors (CD8 or CD4) dock are highly conserved to ensure the immune system can always communicate with these molecules, regardless of the specific antigen being presented.

3. Conservation within the Individual: Stable (with a catch)

Within a single person, your HLA genotype is "conserved" in every nucleated cell of your body. However, as noted in the platform workflow you shared, cancers can break this rule:

HLA Loss of Heterozygosity (LOH): Cancers often undergo "evolution" within the body. To survive, a tumor might delete a specific HLA allele.
Functional Loss: Even if the gene is still there, the tumor may stop producing the protein. This means the HLA is genetically conserved in the DNA, but not conserved in the phenotype (the actual protein on the cell surface).

Summary Table

Context	Is it Conserved?	Why?
Evolutionary Sequence	No	It is the most polymorphic (diverse) part of our DNA.
3D Protein Structure	Yes	The basic "cradle" shape is essential for immune function.
Individual Genotype	Yes	Your DNA sequence stays the same across your tissues.
Tumor Phenotype	Often No	Cancers frequently lose HLA expression to hide from T-cells.

Are you looking at conservation from a bioinformatics perspective (sequence alignment), or are you considering how "stable" these markers are when designing the vaccine candidates mentioned in your diagram?

This image details the Patient Timeline for a personalized neoantigen vaccine clinical trial. It bridges the gap between the identification platform you shared earlier and the actual clinical administration of the treatment.

The timeline is divided into two phases: The Manufacturing Phase (the preparation) and the Treatment Phase (the 24-week clinical schedule).

1. The Manufacturing Phase (Approx. 7–9 Weeks)

This is the "turnaround time" required to create a custom vaccine once the patient is enrolled.

Step 1: Sequencing (2 weeks): Obtaining the raw data via Tumor WES, PBMC (Peripheral Blood Mononuclear Cell) WES for normal DNA comparison, and Tumor RNA-seq.
Step 2: Bioinformatics (1 week): Running the algorithms mentioned in your first image (Mutect2, NetMHCpan, etc.) to call variants, genotype HLA, and predict the best neoantigens.
Step 3: Synthesis (4–6 weeks): Designing SLPs (Synthetic Long Peptides), manufacturing them in a sterile facility, and formulating them with Poly-ICLC (an adjuvant that "wakes up" the immune system).

2. The Vaccination Strategy

The bottom left of the image explains the logistics of the injection:

Intramuscular: The vaccine is injected into the muscle.
10-20 Peptides: The vaccine isn't just one target; it’s a "cocktail" of 10 to 20 different identified neoantigens.
4 Pools (A, B, C, D): These peptides are divided into four groups. As shown on the human silhouette, these are injected into different anatomical sites (likely both arms and both legs) to maximize exposure to different lymph node stations.

3. The 24-Week Clinical Schedule

The timeline shows what happens after the vaccine is ready (starting at Week 0):

Priming Phase (Weeks 0–4): A dense schedule of vaccinations (the syringe icons) to prime the immune system.
Booster Phase (Weeks 12 & 20): Follow-up injections to maintain the immune memory.
Immune Monitoring (Orange Triangles): Frequent ELISpot assays are performed. This test measures how many T-cells are responding to the neoantigens in the vaccine.
Clinical Assessment: * Follow-up visits (Blue bars): General clinical check-ups.
- Imaging visits (Green bars): CT or MRI scans at weeks 10 and 18 to physically measure if the tumor is shrinking.

Summary of Milestones

Total "Vein-to-Vein" Time: It takes nearly 2 months from biopsy to the first injection.
Intensive Monitoring: The ELISpot testing starts before the first vaccine (baseline) and continues throughout to track the "clonotype expansion" of the patient's T-cells.

Since you’re managing an image core, are you involved in the Imaging visits (weeks 10 and 18) for this protocol, or is your focus more on the early-stage Tumor RNA/DNA analysis?

The process of initiating a T-cell response through peptide vaccination is a carefully orchestrated biological "handshake" that requires both a specific target and a "danger signal."

1. Why Peptides Initiate a T-Cell Response

Peptides themselves are simply short chains of amino acids. To trigger an immune response, they must successfully navigate the Signal 1, 2, 3 model:

Signal 1 (Recognition): When injected, the Synthetic Long Peptides (SLPs) are taken up by Antigen-Presenting Cells (APCs), such as dendritic cells. These cells chop the peptides into smaller fragments and "present" them on HLA molecules. T-cells use their T-cell Receptors (TCR) to "read" these HLA-peptide complexes.
Signal 2 (Co-stimulation): The immune system doesn't attack everything it sees. The Poly-ICLC adjuvant mentioned in your timeline acts as a "danger signal." It mimics a viral infection, telling the APC to express co-stimulatory molecules (like CD80/86). Without this, the T-cell would become "anergic" (unresponsive) or die.
Signal 3 (Cytokine Milieu): The activated APC secretes cytokines (like IL-12) that tell the T-cell what kind of "warrior" to become (e.g., a Cytotoxic CD8+ T-cell to kill tumor cells).

2. Why Injection Sites Affect the Immune Repertoire

The decision to use four different pools (A, B, C, D) at different sites (arms and legs) is a strategic move to maximize the breadth and diversity of the immune response.

Lymph Node Drainage

Each injection site drains to a specific set of sentinel lymph nodes (e.g., axillary nodes for the arms, inguinal nodes for the legs).

Local Competition: If you inject all 20 peptides into a single spot, the dendritic cells in that area become "crowded." Peptides with the highest binding affinity will "win" the competition for HLA docking, and your immune system might only learn to recognize 2 or 3 targets (immunodominance).
Niche Creation: By splitting the peptides into four pools at four sites, you are essentially opening four different "training camps." This allows the immune system to react to a wider repertoire of neoantigens simultaneously without them competing for the same real estate on the same dendritic cells.

Clonal Expansion and Circulation

Once T-cells are activated in these diverse lymph nodes, they enter the bloodstream.

The "Search Party": T-cells activated in the arm and T-cells activated in the leg will eventually meet in the blood and migrate together toward the tumor.
Breadth vs. Depth: This multi-site approach ensures that if the tumor "hides" one target (through mutation or HLA loss), the patient still has a broad repertoire of other T-cells (clonotypes) trained at different sites ready to attack other targets.

Summary Table: Single vs. Multi-Site Injection

Feature	Single Site Injection	Multi-Site (Pools A-D)
Lymph Node Engagement	Limited to one region.	Engages multiple drainage basins.
Antigen Competition	High (risk of "Immunodominance").	Low (promotes broad repertoire).
T-cell Diversity	Narrower range of T-cell clones.	Diverse "army" of T-cell clonotypes.
Tumor Escape Risk	High (easier for tumor to hide).	Low (multiple targets tracked).

Are you analyzing the ELISpot data from these different pools to see which injection site produced the strongest response?

T-cell exhaustion is a state of progressive dysfunction that occurs when the immune system faces a battle it cannot win quickly. In the context of the neoantigen vaccine platform you're looking at, understanding when this occurs is critical for the "Booster" and "ELISpot" monitoring phases.

Exhaustion typically occurs under the following three conditions:

1. Chronic Antigen Persistence (The Primary Driver)

This is the most common cause. Instead of an "acute" infection that is cleared in days, T-cells are exposed to the target (neoantigen) for weeks or months.

The "Tug-of-War": During the 24-week timeline in your second image, if the tumor is not shrinking, the T-cells are constantly seeing the neoantigen.
The 2–4 Week Window: Research (often in LCMV models) shows that if T-cells are exposed to a persistent antigen for more than 2 to 4 weeks, they begin to undergo epigenetic changes that lock them into an "exhausted" state. They can no longer transition back to healthy memory cells.

2. High "Antigenic Load"

The sheer volume of the target matters.

Tumor Burden: If the patient has a high tumor burden (large or multiple metastatic sites), the T-cells are overwhelmed.
In the Workflow: This is why clinical trials often combine vaccines with Checkpoint Inhibitors (like anti-PD-1). The vaccine creates the "army," and the checkpoint inhibitor prevents them from "fatiguing" (exhausting) due to the high load.

3. Lack of "CD4+ Help"

In your first image, the platform focuses heavily on identifying peptides for HLA.

If the vaccine only triggers CD8+ (killer) T-cells without enough CD4+ (helper) T-cell activation, the CD8+ cells exhaust much faster.
CD4+ cells provide "maintenance" signals (like IL-2 and IL-21) that keep the killers active. Without this help, the killer cells essentially run out of fuel.

How to recognize exhaustion in your trial data:

If you are reviewing ELISpot or Flow Cytometry results, look for these "red flags":

Stage	Biomarkers / Signs	Functional Status
Early Exhaustion	Loss of IL-2 production	Can still kill, but stops multiplying.
Intermediate	High PD-1 and LAG-3; loss of TNF- $\alpha$	Killing capacity drops significantly.
Terminal Exhaustion	High TIM-3; loss of IFN- $\gamma$	The cell is "blind" and essentially useless.
Final Stage	Physical Deletion	The T-cell undergoes apoptosis and disappears from the repertoire.

Why this matters for the "Patient Timeline":

The Boosters (Weeks 12, 20): These are timed to try and "re-invigorate" the T-cell population before they reach terminal exhaustion.
The Adjuvant (Poly-ICLC): It’s included specifically to delay this process by keeping the "danger signal" strong, which helps prevent the T-cells from switching into the "off" (exhausted) mode too early.

Are you seeing a decline in IFN-gamma levels in the later-week ELISpot results? That would be a classic sign that the T-cell repertoire is beginning to exhaust.

The combination of a personalized cancer vaccine and immune checkpoint inhibitors (ICIs) is often described as "fueling the engine and releasing the brakes." Individually, these therapies often face a "bottleneck" that the other is uniquely equipped to solve.

1. The Synergistic Mechanism: "Push" vs. "Pull"

The two therapies work at different stages of the T-cell's journey to the tumor:

The Vaccine (The Push/Fuel): The primary limitation of the immune system in cancer is ignorance. The vaccine solves this by "teaching" the immune system exactly what the tumor looks like (the neoantigens from your first image). It creates a "push" by forcing the production of a massive army of new, tumor-specific T-cells.
The Checkpoint Inhibitor (The Pull/Brakes): The primary limitation of those new T-cells is exhaustion. Once they reach the tumor, the cancer uses "brakes" (like PD-L1) to shut them down. ICIs (like anti-PD-1) "release" these brakes, allowing the vaccine-generated T-cells to actually perform their job inside the hostile tumor environment.

2. Solving the "Cold Tumor" Problem

In clinical oncology, tumors are often categorized by their immune activity:

"Hot" Tumors: Already have T-cells inside them but are being suppressed. ICIs work well here alone.
"Cold" Tumors: Have no T-cells at all. ICIs fail here because there is no "army" to unleash.

The Combination Strategy: The vaccine turns a Cold tumor into a Hot one by priming T-cells and directing them to the tumor site. The ICI then ensures that once they arrive, they aren't immediately deactivated.

3. Preventing "Early Exhaustion"

As we discussed earlier, T-cell exhaustion occurs when cells are exposed to high antigen loads for too long.

The Problem: A vaccine increases the number of T-cells, but those cells can quickly become exhausted because the tumor is still there.
The Solution: Giving an ICI alongside the vaccine (as seen in many clinical trials) prevents the "Terminal Exhaustion" state. It keeps the T-cells in a "Progenitor Exhausted" or "Stem-like" state, where they can continue to multiply and kill for a much longer duration.

Summary of Synergy

Feature	Cancer Vaccine	Checkpoint Inhibitor (ICI)	The Combination
Primary Goal	Generate New T-cells.	Resuscitate Existing T-cells.	Create a massive, unstoppable army.
Targeting	Specific (Neoantigens).	General (Releases all T-cells).	Specific attack with high intensity.
Tumor Status	Turns "Cold" to "Hot".	Only works on "Hot" tumors.	Effective against most tumor types.
Analogy	Stepping on the Gas.	Releasing the Emergency Brake.	High-speed pursuit.

Clinical Context

In the Patient Timeline you provided, the "Follow-up visits" and "Imaging visits" are the points where clinicians often decide to add an ICI if the vaccine alone isn't shrinking the tumor fast enough. By combining them, you maximize the repertoire (from the vaccine) and the durability (from the ICI).

Does the protocol you are working with currently involve a specific checkpoint inhibitor, like Pembrolizumab (anti-PD-1) or Ipilimumab (anti-CTLA-4)?

Actually, that is a common point of confusion, but most current immune checkpoint inhibitors (ICIs) are not small molecules—they are large monoclonal antibodies.

However, the field is shifting, and there is a huge effort to develop small-molecule versions. Here is the breakdown of why they are different and where we stand today:

1. The Standard: Monoclonal Antibodies (mAbs)

The drugs you hear about most (like Pembrolizumab/Keytruda, Nivolumab, or Ipilimumab) are large proteins.

Size: They are roughly 150,000 Daltons (very large).
Mechanism: They work like a physical "shield" or "cap." They bind to the surface of the T-cell (PD-1) or the tumor cell (PD-L1) to physically block them from touching each other.
Delivery: Because they are proteins, they would be digested in the stomach, so they must be injected (IV infusion).

2. The New Frontier: Small Molecule Checkpoint Inhibitors

Researchers are actively working on small-molecule versions (like CA-170 or MAX-10181). These are what you might be thinking of:

Size: Usually under 500 Daltons.
Mechanism: Instead of just "capping" the surface, they can enter cells or get into the small "nooks and crannies" of the protein-protein interface to disrupt the signaling from the inside.
Advantage: They could potentially be taken as a pill (oral) instead of an infusion, which would be much easier for the patients on the 24-week timeline you shared.
Tissue Penetration: Small molecules can get into dense tumors (or across the blood-brain barrier) much better than bulky antibodies.

Comparison at a Glance

Feature	Monoclonal Antibodies (Current)	Small Molecules (Emerging)
Example	Pembrolizumab, Nivolumab	CA-170, GS-4224
Administration	Injection / Infusion	Oral (Pills)
Half-life	Long (Weeks)	Short (Hours/Days)
Cost	Very High	Potentially Lower
Control	Hard to "turn off" quickly.	Easy to stop (washout is fast).

Why this matters for your workflow:

In the Patient Timeline you showed, the vaccine is "Intramuscular" and the adjuvant is Poly-ICLC. If the checkpoint inhibitor used in a trial like this were a small molecule, it could significantly simplify the "Follow-up visits," as the patient might be able to take their "checkpoint pill" at home between the clinic-based vaccine injections.

To be direct: If you are looking at a standard clinical protocol today, it’s almost certainly using antibodies (large proteins). But if you are looking at cutting-edge drug discovery or a Phase I trial, you might be seeing the first generation of small-molecule inhibitors.

Are the drugs in your specific project being administered via IV infusion, or are you looking at an oral clinical trial?

Poly-ICLC (also known by the brand name Hiltonol) is a synthetic "viral mimic" used as a powerful adjuvant in vaccines.

In your patient timeline, it is the secret sauce that prevents the immune system from ignoring the 10–20 peptides you've injected.

1. What is it chemically?

It is a synthetic, double-stranded RNA (dsRNA) complex.

Poly I: Polyinosinic acid
Poly C: Polycytidylic acid
L-C: It is stabilized with L-lysine and carboxymethylcellulose.
- Why the stabilization? Raw RNA is destroyed almost instantly by enzymes (RNases) in the human body. The "LC" part acts like a protective suit, allowing the RNA to survive long enough to trigger the immune system.

2. How does it work? (The "Danger Signal")

Our immune systems have evolved to be terrified of double-stranded RNA because it usually means a virus is replicating inside our cells. Poly-ICLC exploits this by activating two specific "burglar alarms" in your cells:

TLR3 (Toll-Like Receptor 3): Found on the surface and inside endosomes of dendritic cells.
MDA5 (Melanoma Differentiation-Associated protein 5): Found in the cytoplasm.

When these sensors detect Poly-ICLC, they trigger a massive release of Type I Interferons (IFN- $\alpha$ and IFN- $\beta$ ). This creates an "inflamed" environment that tells the T-cells: "Whatever protein you just saw (the neoantigens), it's dangerous! Attack it!"

3. Why use it in this Neoantigen Platform?

Without Poly-ICLC, the 10–20 peptides in your vaccine might be seen by the body as "self" or harmless debris.

Maturity: It forces dendritic cells to "mature" and become professional teachers for T-cells.
Th1 Response: It specifically steers the immune system toward a Th1/CD8+ cytotoxic response, which is exactly what you need to kill tumor cells.
Durability: As we discussed regarding exhaustion, Poly-ICLC helps keep the immune response active for a longer period, which is why it’s included in every injection on your 24-week timeline.

Comparison: Why not just use "Regular" RNA?

Feature	Natural dsRNA	Poly-ICLC
Stability	Degraded in seconds.	Stable for hours/days in tissue.
Potency	Low (due to degradation).	Extremely High.
Safety	Unpredictable.	Well-studied and "tunable" for clinical trials.

Summary for your Workflow:

In the image you uploaded, the "Formulate with Poly-ICLC" step at week 4–6 is where the bioinformatics predictions are turned into an actual "live" drug. It is the component that transforms a list of amino acids into an active immunotherapy.

Since your research focuses on genomic stability and DNA repair (specifically things like PARP1), Poly-ICLC is interesting because it essentially triggers a "controlled" version of the inflammatory stress that often occurs when DNA repair mechanisms fail in cancer cells.

It seems counterintuitive—if there is more tumor, shouldn't there be more "targets" for the immune system to find? In reality, a high Tumor Burden creates a series of biological hurdles that can effectively "drown out" the immune response generated by the platform you shared.

Here are the four primary reasons why a larger tumor mass often leads to a poorer response:

1. The "Immunosuppressive Shield" (The Microenvironment)

A large tumor is not just a pile of cancer cells; it is an entire ecosystem. As tumors grow, they recruit "suppressor" cells that act like a security team for the cancer:

Tregs & MDSCs: Large tumors have high concentrations of Regulatory T-cells (Tregs) and Myeloid-Derived Suppressor Cells (MDSCs). These cells physically and chemically shut down the "killer" T-cells produced by your vaccine.
Cytokine Sinks: Large tumors produce massive amounts of inhibitory cytokines like TGF- $\beta$ and IL-10, which create a "no-fly zone" for the immune system.

2. T-Cell Exhaustion & "Antigen Overload"

We discussed earlier that exhaustion occurs when T-cells are exposed to antigen for too long.

The Math of Failure: In a small tumor, a vaccine might produce enough T-cells to kill the cancer quickly. In a high-burden patient, the T-cells are outnumbered.
They enter the tumor, kill a few cells, but are immediately hit with more antigen. This constant stimulation without a "break" fast-tracks them into Terminal Exhaustion (the high PD-1/TIM-3 state), where they stop working entirely.

3. Metabolic Competition (The "Starvation" Effect)

Tumors are metabolically "greedy." They consume massive amounts of glucose and amino acids (like Tryptophan) to fuel their rapid growth.

The Waste Problem: They also produce high levels of lactic acid, which lowers the pH of the surrounding tissue.
T-cell Dysfunction: T-cells require glucose to power their "killing" machinery. In a high-burden environment, the tumor literally starves the T-cells and poisons them with acid, making them sluggish and ineffective.

4. Clonal Heterogeneity (The "Shell Game")

The larger a tumor grows, the more it mutates. This is known as spatial heterogeneity.

The Target Gap: The vaccine in your workflow is designed based on a biopsy (usually from one site). In a high-burden patient with multiple metastases, the tumor in the "liver" might have different mutations than the tumor in the "lung."
The T-cells might successfully attack the "primary" targets but miss the "sub-clones" in other areas, allowing the cancer to escape.

Comparison: Low vs. High Tumor Burden

Feature	Low Tumor Burden	High Tumor Burden
Effector-to-Target Ratio	High (More T-cells per cancer cell).	Low (T-cells are outnumbered).
Metabolic Environment	Relatively Normal.	Acidic, hypoxic, and glucose-depleted.
Antigen Variation	Uniform (Easier to target).	Heterogeneous (Multiple "escapes").
Immune State	Primed / Active.	Exhausted / Suppressed.

Clinical Significance for your Timeline

This is why many clinical protocols aim to treat patients in the "adjuvant" setting (after surgery has removed the main tumor mass). By reducing the burden through surgery or radiation first, the "Neoantigen Vaccine" has a much higher chance of success because the remaining "micro-metastases" are easier for the immune repertoire to manage.

In your current research involving genomic stability, are you seeing that higher levels of DNA damage (which can lead to higher burden) also correlate with these immunosuppressive "shield" markers in your samples?

Targeting tumor heterogeneity is perhaps the single most important factor in the success of the personalized vaccine platform you're studying. If a vaccine only targets one or two mutations, it leaves the door wide open for the cancer to survive and evolve.

1. Why cover heterogeneity? (The "Anti-Escape" Strategy)

Tumors are not uniform; they are "mosaics" of different cell populations (clones).

The "Whack-a-Mole" Problem: If your vaccine only targets a mutation found in the "primary" clone, the "sub-clones" that don't carry that specific mutation will simply keep growing. This is called immunoediting—the immune system kills the easy targets, leaving behind the most resistant ones.
Spatial Heterogeneity: As we discussed with the "pools A-D," different metastatic sites (liver vs. lung) might have different genetic profiles. A multi-neoantigen approach ensures that T-cells are trained to recognize a broad "spectral fingerprint" of the cancer, regardless of where it is hiding in the body.
Trunk vs. Branch Mutations: Algorithms try to prioritize "Trunk" mutations (found in every cancer cell) but also include "Branch" mutations (found in only some cells). By covering both, the vaccine acts like a wide-net search party rather than a single sniper.

2. How many neoantigens are usually used?

While the first image you shared mentions identifying many targets, manufacturing limitations and biological "crowding" usually restrict the final vaccine to a specific number.

The "Standard" Range: Most clinical trials (like the NeoVax trials at Dana-Farber) typically use 10 to 20 unique neoantigens.
The "High-Density" Exception: Some newer trials are pushing this boundary, using up to 40 neoantigens (as seen in recent brain cancer trials).
The "Pooling" Logic: Because you can't easily fit 20 different long peptides into a single small injection without them aggregating or competing for HLA space, they are "pooled" (e.g., 5 peptides per pool) and injected at different sites (A, B, C, and D) as seen in your timeline.

Vaccine Type	Typical Number of Neoantigens	Rationale
Peptide (SLP)	10–20	Balances manufacturing cost with broad coverage.
mRNA (e.g., BioNTech)	20+	Easier to encode many targets on a single "string" of RNA.
Personalized DNA	Up to 40	High capacity for multiple sequences.

3. The Quality vs. Quantity Trade-off

Researchers don't just pick the first 20 mutations they find. They use the workflow in your first image to rank them based on:

Clonality: Is it a "Trunk" mutation?
Binding Affinity: Does it stick well to the patient's HLA?
Expression: Is the tumor actually "making" this protein? (RNA-seq check).

In short: You target many neoantigens to prevent the tumor from "evolving away" from the treatment. Using 20 peptides is the current clinical "sweet spot" for balancing a broad immune repertoire with the logistical challenges of making a custom drug for one person in under 8 weeks.

Given your role as an image core manager, do you see this heterogeneity reflected in the tumor biopsies you process—perhaps via multiplexed imaging or IHC?

In the context of the neoantigen identification platform you are studying, TESLA does not refer to the car company. It stands for the Tumor Neoantigen Selection Alliance.

Its role is essentially to serve as the "gold standard" or the ultimate testing ground for the bioinformatics tools you see in your first diagram (like Mutect2, NetMHCpan, and pVACseq).

1. The Purpose of TESLA

When the field of personalized vaccines began, every lab had its own algorithm to predict which mutations would make the best vaccines. However, many of these predictions failed in real patients. TESLA was formed as a global community effort (organized by the Parker Institute for Cancer Immunotherapy) to find out which algorithms actually work.

2. How the TESLA Role Functions

TESLA operates as a massive "benchmarking" competition:

The Challenge: The alliance provided a common set of tumor and normal sequencing data to 28 different research groups worldwide.
The Task: Each group used their own internal pipeline (similar to the workflow in your first image) to predict the top neoantigens.
The Validation: The alliance then physically synthesized all those predicted peptides and tested them against real human T-cells to see which ones actually triggered an immune response.

3. Key Findings & The "TESLA Parameters"

The role of the TESLA project was to identify the "hidden rules" of what makes a good neoantigen. They discovered that simply having high binding affinity to HLA isn't enough. To be successful, an algorithm (like the one in your platform) should also consider:

MHC Stability: How long the peptide stays "preserved" in the HLA cradle (as we discussed earlier).
Foreignness: How different the mutation looks compared to the "normal" version of the protein.
Expression: Ensuring the RNA levels are high enough for the protein to be visible to the immune system.

4. Why this matters for the "Patient Timeline"

The bioinformatics step in your timeline—the "1 week" turnaround for neoantigen prediction—is only possible because of the rules established by TESLA. The software tools mentioned in your image were likely refined using the data and benchmarks that the TESLA alliance published.

In summary: TESLA is the collaborative framework that validated the math behind the platform you are analyzing. It ensures that when you pick those 20 peptides for the vaccine, they have the highest mathematical probability of actually working in the patient.

Are you looking at the specific scoring parameters for your neoantigen candidates, or perhaps comparing different algorithms used within your core facility?